<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565369</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A08</org_study_id>
    <nct_id>NCT01565369</nct_id>
  </id_info>
  <brief_title>Evaluation of Physician Training Methods to Read Florbetapir-PET Scans</brief_title>
  <official_title>Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Validation of Binary Image Rating Methodology Using Amyloid Histopathology at Autopsy as the Reference Standard.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is re-read of brain amyloid positron emission tomography (PET)
      scans acquired in previous florbetapir F 18 clinical studies by readers trained using updated
      reading methodology. The scans in this study came from subjects who had an autopsy to reveal
      the subject's true amyloid status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Sensitivity will be calculated as the percent of true positives (as determined by the reference standard, moderate or frequent amyloid plaque at autopsy) that are correctly identified as amyloid positive by the PET scan read. Reported as the median sensitivity of the nine readers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Specificity will be calculated as the percent of true negatives (as determined by the reference standard, no or sparse amyloid plaque at autopsy) that are correctly identified as amyloid negative by the PET scan read. Reported as the median specificity of the nine readers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-reader Agreement</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Percentage of individual scan reads that agreed or disagreed with the majority read across nine readers</description>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <description>IV injection, 370MBq (10mCi), single dose</description>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Study A07[NCT00857415]):

          -  Have a projected life expectancy of â‰¤ 6 months as determined by the principal
             investigator (e.g. terminal medical condition) or are already enrolled in a
             longitudinal study of aging with an autopsy component;

          -  Can tolerate a 10 minute PET scan; and

          -  Give informed consent for study procedures and brain donation consistent with the
             legal requirements of the State in which they are enrolled and the State in which they
             die.

        Exclusion Criteria (Study A07[NCT00857415]):

          -  Have primary brain tumor, known metastases to the brain, central nervous system (CNS)
             lymphoma;

          -  Have any major, focal structural loss of brain matter;

          -  Are aggressively being treated with life sustaining measures (e.g. currently on
             respirator; receiving high dose chemotherapy);

          -  Have a clinically significant infectious disease, including Acquired Immune Deficiency
             Syndrome (AIDS), Human Immunodeficiency Virus (HIV) infection, previous positive test
             for hepatitis or HIV or Creutzfeldt-Jakob disease (CJD);

          -  Are receiving any investigational medications, or have participated in a trial with
             investigational medications within the last 30 days;

          -  Have ever participated in an experimental study with an amyloid targeting agent (e.g.
             anti-amyloid immunotherapy, secretase inhibitor);

          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to
             the study imaging session; or

          -  Are females of childbearing potential who are pregnant or not using adequate
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <results_first_submitted>April 6, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2012</results_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>18F-AV-45</keyword>
  <keyword>florbetapir F 18</keyword>
  <keyword>Diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>NO SUBJECTS WERE ENROLLED IN THIS STUDY - this study re-read scans obtained in other clinical studies</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All A07 Autopsy Subjects</title>
          <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All A07 Autopsy Subjects</title>
          <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.3" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</title>
        <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Sensitivity will be calculated as the percent of true positives (as determined by the reference standard, moderate or frequent amyloid plaque at autopsy) that are correctly identified as amyloid positive by the PET scan read. Reported as the median sensitivity of the nine readers.</description>
        <time_frame>50-60 min after injection</time_frame>
        <population>19 of the 35 subjects had moderate or frequent plaques at autopsy</population>
        <group_list>
          <group group_id="O1">
            <title>All A07(NCT00857415) Autopsy Subjects</title>
            <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07(NCT00857415)</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</title>
          <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Sensitivity will be calculated as the percent of true positives (as determined by the reference standard, moderate or frequent amyloid plaque at autopsy) that are correctly identified as amyloid positive by the PET scan read. Reported as the median sensitivity of the nine readers.</description>
          <population>19 of the 35 subjects had moderate or frequent plaques at autopsy</population>
          <units>percentage of true positives</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="84.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</title>
        <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Specificity will be calculated as the percent of true negatives (as determined by the reference standard, no or sparse amyloid plaque at autopsy) that are correctly identified as amyloid negative by the PET scan read. Reported as the median specificity of the nine readers.</description>
        <time_frame>50-60 min after injection</time_frame>
        <population>16 of the 35 subjects had none or sparse plaques at autopsy</population>
        <group_list>
          <group group_id="O1">
            <title>All A07 Autopsy Subjects</title>
            <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07(NCT00857415)</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque</title>
          <description>Nine readers blinded to all clinical information using the binary read methodology (amyloid positive/negative). Specificity will be calculated as the percent of true negatives (as determined by the reference standard, no or sparse amyloid plaque at autopsy) that are correctly identified as amyloid negative by the PET scan read. Reported as the median specificity of the nine readers.</description>
          <population>16 of the 35 subjects had none or sparse plaques at autopsy</population>
          <units>percentage of true negatives</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="68.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter-reader Agreement</title>
        <description>Percentage of individual scan reads that agreed or disagreed with the majority read across nine readers</description>
        <time_frame>50-60 min after injection</time_frame>
        <population>315 scans = 35 subjects x 9 readers</population>
        <group_list>
          <group group_id="O1">
            <title>All A07(NCT00857415) Autopsy Subjects</title>
            <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07(NCT00857415)</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-reader Agreement</title>
          <description>Percentage of individual scan reads that agreed or disagreed with the majority read across nine readers</description>
          <population>315 scans = 35 subjects x 9 readers</population>
          <units>percentage of scans</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>florbetapir PET scan reads</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agreed with majority read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discrepant with majority read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Fleiss' kappa</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>evaluated at the .05 significance level</p_value_desc>
            <method>Fleiss' kappa</method>
            <param_type>Fleiss' kappa</param_type>
            <param_value>0.8547</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0282</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No subjects received florbetapir in this study. This study consisted of rereads of scans previously acquired in another clinical study (A07).</desc>
      <group_list>
        <group group_id="E1">
          <title>All A07 Autopsy Subjects</title>
          <description>Subjects who had a valid florbetapir-PET scan and came to autopsy in Study A07</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-798-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

